产品名称	FaDu人咽鳞癌细胞
货号	ZQ0229
产品介绍	1968年从一位患者的下咽肿瘤穿刺活检中建立的了FaDu细胞株。 发现已建立的细胞系在细胞质中含有张力丝束，并且桥粒区域在细胞边界处很突出。该细胞系经常用于医学研究，特别是聚焦于头颈部癌症的生物学研究。这些细胞表现出上皮形态，在培养条件下是贴壁生长的。FaDu以其强健的生长能力而闻名，常被用于实验中以理解癌细胞增殖、对治疗药物的反应以及与癌症进展和转移相关的基因表达。 在科学研究中，FaDu细胞在检验放疗和化疗治疗的效果方面发挥了重要作用，为细胞对DNA损伤和修复机制的反应提供了洞见。该细胞系也被用于探索癌症中涉及的分子途径，例如在头颈部癌症中经常发生改变的EGFR信号通路。FaDu细胞的多功能性和相关性使它们成为肿瘤学研究的宝贵模型，有助于发展靶向治疗并从分子水平上理解癌细胞生物学。
种属	人
性别/年龄	男/56岁
组织	咽
疾病	鳞状细胞癌
细胞类型	肿瘤细胞
形态学	上皮细胞
生长方式	贴壁
倍增时间	大约30~50小时
培养基和添加剂	MEM（含NEAA）培养基(中乔新舟  货号:ZQ-300)+10%胎牛血清（中乔新舟 货号：ZQ0500）+1%双抗（中乔新舟 货号：CSP006）
推荐完全培养基货号	ZM0229
生物安全等级	BSL-1
STR位点信息	Amelogenin: None detected D3S1358: 17,18 TH01: 8 D21S11: 31.2 D18S51: 16 Penta_E: 17,19 D5S818: 12 D13S317: 8,9 D7S820: 11,12 D16S539: 11 CSF1PO: 12 Penta_D: 11 vWA: 15,17 D8S1179: 13 TPOX: 11 FGA: 25 D19S433: 14,16 D2S1338: 19
培养条件	95%空气，5%二氧化碳；37℃
抗原表达/受体表达	***
基因表达	***
保藏机构	ATCC; HTB-43 BCRC; 60214 BCRJ; 0301 DSMZ; ACC-784
供应限制	仅供科研使用

货号	ZM0229
发货规格	活细胞：T25培养瓶*1瓶或者1ml 冻存管*1支（细胞量约为5 x 10^5 cells/vial）二选一
发货形式	活细胞：常温运输；冻存管：干冰运输
储存温度	活细胞：培养箱；冻存管：液氮罐
产地	中国
供应限制	仅供科研使用

论文标题： Genetic variants associated with expression of TCF19 contribute to the risk of head and neck cancer in Chinese population
DOI： 10.1136/jmedgenet-2020-107410
发表时间： 2022-04-01
期刊： JOURNAL OF MEDICAL GENETICS
影响因子： 5.941
货号： ZQ0229
产品名称： FaDu cells
原文链接： https://jmg.bmj.com/content/59/4/335.abstract

论文标题： Dihydroartemisinin represses oral squamous cell carcinoma progression through downregulating mitochondrial calcium uniporter
DOI： 10.1080/21655979.2021.2012951
发表时间： 2021-12-29
期刊： Bioengineered
影响因子： 3.269
货号： ZQ0229
产品名称： FaDu cells
原文链接： https://www.tandfonline.com/doi/abs/10.1080/21655979.2021.2012951

论文标题： Silencing Ras-Related C3 Botulinum Toxin Substrate 1 Inhibits Growth and Migration of Hypopharyngeal Squamous Cell Carcinoma via the P38 Mitogen-Activated Protein Kinase Signaling Pathway
DOI： 10.12659/MSM.907468
发表时间： 2018-02-07
期刊： MEDICAL SCIENCE MONITOR
影响因子： 2.649
货号： ZQ0229
产品名称： FaDu cells

原文链接： https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812251/

PubMed=4332311; DOI=10.1002/1097-0142(197201)29:1<117::AID-CNCR2820290119>3.0.CO;2-R
Rangan S.R.S.
A new human cell line (FaDu) from a hypopharyngeal carcinoma.
Cancer 29:117-121(1972)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=2990217
Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.
Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.
Am. J. Pathol. 119:361-366(1985)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3138611; DOI=10.1177/019459988809800603
Wustrow T.P.U., Raffael A., Valet G.K.
Multiparametric flow cytometry of human squamous cell carcinoma lines from the head and neck.
Otolaryngol. Head Neck Surg. 98:552-557(1988)

PubMed=1394225
Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., Casey G.
Frequent p53 mutations in head and neck cancer.
Cancer Res. 52:5997-6000(1992)

DOI=10.1016/B978-0-12-333530-2.50007-1
Carey T.E.
Head and neck tumor cell lines.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994)

PubMed=8552396
Patel A.M., Incognito L.S., Schechter G.L., Wasilenko W.J., Somers K.D.
Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines.
Oncogene 12:31-35(1996)

PubMed=9815580
Wu Y.-G., Palad A.J., Wasilenko W.J., Blackmore P.F., Pincus W.A., Schechter G.L., Spoonster J.R., Kohn E.C., Somers K.D.
Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole.
Clin. Cancer Res. 3:1915-1921(1997)

PubMed=11799138; DOI=10.1177/002215540205000207
Eicheler W., Zips D., Dorfler A., Grenman R., Baumann M.
Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection.
J. Histochem. Cytochem. 50:197-204(2002)

PubMed=17848307; DOI=10.1016/j.ijrobp.2007.04.082
Yarbrough W.G., Whigham A., Brown B., Roach M., Slebos R.J.C.
Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas.
Int. J. Radiat. Oncol. Biol. Phys. 69:S98-S101(2007)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21833476; DOI=10.3892/or.2011.1418
Ma J.-K., Lu S.-M., Yu L., Tian J.-J., Li J.-F., Wang H.-B., Xu W.
FaDu cell characteristics induced by multidrug resistance.
Oncol. Rep. 26:1189-1195(2011)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23613873; DOI=10.1371/journal.pone.0061555
Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A., Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.
DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.
PLoS ONE 8:E61555-E61555(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=25888065; DOI=10.1016/j.molonc.2015.03.008
Stanam A., Love-Homan L., Joseph T.S., Espinosa-Cotton M., Simons A.L.
Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.
Mol. Oncol. 9:1371-1383(2015)

PubMed=26122845; DOI=10.1158/0008-5472.CAN-15-0528
Stoepker C., Ameziane N., van der Lelij P., Kooi I.E., Oostra A.B., Rooimans M.A., van Mil S.E., Brink A., Dietrich R., Balk J.A., Ylstra B., Joenje H., Feller S.M., Brakenhoff R.H.
Defects in the Fanconi anemia pathway and chromatid cohesion in head and neck cancer.
Cancer Res. 75:3543-3553(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

CLPUB00484

Xu Z.-H., Sun W.-W., Hang J.-B., Gao B.-L., Hu J.-A.
RNA-seq identified a novel functional MET fusion in head and neck cancer 5-8F cell line.
Int. J. Clin. Exp. Pathol. 9:8308-8317(2016)

PubMed=26754630; DOI=10.1186/s13046-016-0284-4
Hyakusoku H., Sano D., Takahashi H., Hatano T., Isono Y., Shimada S., Ito Y., Myers J.N., Oridate N.
JunB promotes cell invasion, migration and distant metastasis of head and neck squamous cell carcinoma.
J. Exp. Clin. Cancer Res. 35:6.1-6.12(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28476783; DOI=10.21873/anticanres.11555
Hagemann J., Jacobi C., Hahn M., Schmid V., Welz C., Schwenk-Zieger S., Stauber R.H., Baumeister P., Becker S.
Spheroid-based 3D cell cultures enable personalized therapy testing and drug discovery in head and neck cancer.
Anticancer Res. 37:2201-2210(2017)

PubMed=28844650; DOI=10.1016/j.anl.2017.07.011
Cho K.-J., Park E.-J., Kim M.-S., Joo Y.-H.
Characterization of FaDu-R, a radioresistant head and neck cancer cell line, and cancer stem cells.
Auris Nasus Larynx 45:566-573(2017)

PubMed=29156801; DOI=10.18632/oncotarget.21174
Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y., Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.
Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.
Oncotarget 8:86369-86383(2017)

PubMed=30135316; DOI=10.1172/jci.insight.122204
Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A., Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D., Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M., Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R., Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J., McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G., Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
JCI Insight 3:e122204.1-e122204.19(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004
van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I., Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.
Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
Oral Oncol. 98:53-61(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=33802339; DOI=10.3390/cancers13051069
Gottgens E.-L., Ansems M., Leenders W.P.J., Bussink J., Span P.N.
Genotyping and characterization of HPV status, hypoxia, and radiosensitivity in 22 head and neck cancer cell lines.
Cancers (Basel) 13:1069.1-1069.12(2021)

PubMed=34249502; DOI=10.7717/peerj.11645
Zhang G.-H., Tan G.-L., Li T.-Q., Ai J.-G., Song Y.-X., Zhou Z., Xiao J., Li W.
Analysis of ceRNA network of differentially expressed genes in FaDu cell line and a cisplatin-resistant line derived from it.
PeerJ 9:e11645.1-e11645.15(2021)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)